LifeMD (NASDAQ:LFMD) Given “Buy” Rating at HC Wainwright

LifeMD (NASDAQ:LFMD)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 128.83% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. Weiss Ratings upgraded LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research report on Monday, May 4th. Mizuho upgraded LifeMD from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $6.00 to $8.00 in a research report on Monday, March 16th. Finally, Loop Capital set a $10.00 target price on LifeMD in a research report on Thursday, March 12th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, LifeMD has a consensus rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Stock Performance

Shares of NASDAQ LFMD traded up $0.18 during mid-day trading on Tuesday, reaching $4.37. The company had a trading volume of 260,609 shares, compared to its average volume of 1,143,946. LifeMD has a one year low of $2.56 and a one year high of $15.84. The firm has a market cap of $211.33 million, a price-to-earnings ratio of 87.42 and a beta of 2.03. The business’s 50-day simple moving average is $4.15 and its 200 day simple moving average is $3.79.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%.The company had revenue of $50.16 million during the quarter, compared to the consensus estimate of $48.84 million. On average, sell-side analysts anticipate that LifeMD will post 0.04 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LFMD. Caitong International Asset Management Co. Ltd bought a new position in LifeMD in the fourth quarter valued at about $36,000. Magnus Financial Group LLC acquired a new stake in shares of LifeMD during the fourth quarter valued at about $41,000. R Squared Ltd acquired a new stake in shares of LifeMD during the first quarter valued at about $41,000. Jain Global LLC acquired a new stake in shares of LifeMD during the fourth quarter valued at about $45,000. Finally, Quarry LP acquired a new stake in shares of LifeMD during the third quarter valued at about $52,000. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.